



Pressrelease, 2024-03-06
Malmö, Sweden

Resolutions from the Extraordinary General Meeting in aXichem AB (publ)

An extraordinary general meeting of aXichem AB (publ) was held on March 6, 2024.

The extraordinary general meeting decided, in accordance with the board's proposal, to adopt new articles of association whereby the limits regarding the share capital and outstanding shares are changed. After the amendment, the share capital must be a minimum of SEK 4,250,000 and a maximum of SEK 17,000,000, and the company must have a minimum of 21,400,000 shares and a maximum of 85,600,000 shares.

The extraordinary general meeting also decided to approve the board's decision from 1 February 2024 to issue a maximum of 5,374,081 units, consisting of a total of 26,870,405 shares of series A and 26,870,405 warrants of series TO1A.

The record date for the right to participate in the unit issue shall be March 8, 2024. Subscription of units shall take place during the period March 11, 2024 – March 25, 2024.

The right to subscribe for units shall accrue to the company's shareholders with preferential rights. Subscription can also take place without the support of pre-emptive rights in accordance with what appears in the complete issuance decision. For each existing share held on the record date, one unit right is obtained, whereby four unit rights entitle the holder to subscribe for one unit. Each unit consists of five A shares and five warrants of series TO1A.

Each warrant entitles the holder to subscribe for one new A share during the period October 8, 2024 – October 21, 2024 at a subscription price per share to be set at an amount corresponding to 70 percent of the company's share's volume-weighted average price on the Nasdaq First North Growth Market during the period October 1, 2024 – October 7, 2024.

Through the issue, a maximum of 26,870,405 new shares can be issued, and the share capital can increase by a maximum of SEK 5,374,081. Furthermore, a maximum of 26,870,405 warrants can be issued through the issue, and if fully exercised, the share capital can increase by a maximum of SEK 5,374,081.

Full terms and conditions for the rights issue and other information about the company will be found in the EU growth prospectus, which is expected to be published around March 8, 2024. For further details and information about the background and motive for the unit issue, see the company's press release on February 1, 2024.

The information was submitted, through the care of the contact person below, for publication on 6 March 2024, at 11:00 CET.

Company contact:

Torsten Helsing, CEO, aXichem AB

Phone: +46 706 863 355 Email: torsten.helsing@axichem.com

About aXichem

aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio-enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Certified advisor for aXichem is Västra Hamnen Corporate Finance AB.

More information is available at www.axichem.com.